Cargando…

Design of precise third-line therapy for gastric cancer: target or chemotherpy?

Detalles Bibliográficos
Autor principal:	Cho, Jae Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2013
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654126/ https://www.ncbi.nlm.nih.gov/pubmed/23682222 http://dx.doi.org/10.3904/kjim.2013.28.3.297

Ejemplares similares

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
por: Alsina, Maria, et al.
Publicado: (2022)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Molecular Diagnosis for Personalized Target Therapy in Gastric Cancer
por: Cho, Jae Yong
Publicado: (2013)

Targeted Therapies and Developing Precision Medicine in Gastric Cancer
por: Pihlak, Rille, et al.
Publicado: (2023)

Dawning precision treatment for gastric cancer: The latest biomarkers
por: Sun, Keran, et al.
Publicado: (2021)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Precision Medicine for Personalized Cancer Therapy
por: Wong, Ada Hang-Heng, et al.
Publicado: (2015)

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
por: Vidula, Neelima, et al.
Publicado: (2017)

EBV and further emerging directions towards increased precision in gastric cancer treatment
por: Santos, Luana B. C., et al.
Publicado: (2022)

HTA and Gastric Cancer: Evaluating Alternatives in Third- and Fourth-Line Patients
por: Ferrario, Lucrezia, et al.
Publicado: (2023)

Lessons from Interval Gastric Cancer: Read between the Lines
por: Kim, Byung-Wook
Publicado: (2015)

Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done
por: Mare, Marzia, et al.
Publicado: (2022)

Genomic biomarkers: Unveiling the potential for precise cancer therapy response
por: Kaur, Gurjeet, et al.
Publicado: (2023)

Towards precision drug therapy in asthma
por: van Boven, Job F. M.
Publicado: (2022)

Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis
por: Zheng, Yu, et al.
Publicado: (2017)

Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review
por: Chan, Wing-lok, et al.
Publicado: (2019)

Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC
por: Ewer, Michael S., et al.
Publicado: (2021)

Combining targeted therapeutics in the era of precision medicine
por: Papadatos-Pastos, D, et al.
Publicado: (2015)

Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?
por: Mecca, Caterina, et al.
Publicado: (2019)

Clinical Implementation of Precision Medicine in Gastric Cancer
por: Jeon, Jaewook, et al.
Publicado: (2019)

The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “Type” or to “Print”?
por: Cardoso, Fatima, et al.
Publicado: (2018)

Precision antiplatelet therapy for the prevention of ischaemic stroke
por: Wang, David
Publicado: (2021)

Precision oncology and molecular therapies for hepatocellular carcinoma
por: Chen, Liming, et al.
Publicado: (2022)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

The third coronavirus epidemic in the third millennium: what’s next?
por: Čivljak, Rok, et al.
Publicado: (2020)

Clinical proteomics: a driving force for cancer therapeutic target discovery and precision medicine
por: Wang, Hao, et al.
Publicado: (2019)

The full management from first-line to third-line treatments in patients with Her-2–negative advanced gastric cancer
por: Chang, Chunxiao, et al.
Publicado: (2022)

Targeting Akt in cancer for precision therapy
por: Hua, Hui, et al.
Publicado: (2021)

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
por: Ishii, Takahiro, et al.
Publicado: (2020)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
por: Cui, Qingli, et al.
Publicado: (2022)

Cancer-targeted design of bioresponsive prodrug with enhanced cellular uptake to achieve precise cancer therapy
por: Liang, Yuanwei, et al.
Publicado: (2018)

The third year
por: Sherman, Morris
Publicado: (2021)

Adjuvant therapy for gastric cancer – has the standard changed?
por: Valle, J W
Publicado: (2001)

Imaging for radiation treatment planning and monitoring in prostate Cancer: Precision, personalization, individualization of therapy
por: Grosu, Anca-Ligia, et al.
Publicado: (2019)

Gene mutation‐based and specific therapies in precision medicine
por: Wang, Xiangdong
Publicado: (2016)

Toward a More Precise Solution to Asthma Therapy
por: Traber, Katrina E., et al.
Publicado: (2021)

Targeted cancer therapies
por: Yan, Li, et al.
Publicado: (2011)

Targeting in Cancer Therapies
por: Mangues, Ramon, et al.
Publicado: (2016)

Targeted therapies for cancer
por: Zhou, Zhijun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r8239ksskhiveo3085orud5f22